Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects
NCT02260076 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2014-10-09
Summary
To assess the safety and tolerance of 5 mL to 20 mL PEG 400 in multiple rising doses
Conditions
- Healthy
Interventions
- DRUG
-
PEG 400
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2001-09-30
- Primary Completion
- 2002-03-31
More Related Trials
-
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
NCT04323124 ·Status: TERMINATED ·Phase: PHASE1
-
Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429
NCT01117233 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated
NCT01165723 ·Status: COMPLETED ·Phase: PHASE1
-
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
NCT06045000 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers
NCT01002963 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
NCT00097747 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers
NCT00756743 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants
NCT04148209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of EDG-7500 in Healthy Adults
NCT06011317 ·Status: COMPLETED ·Phase: PHASE1
-
First Safety Study in Humans of a Single Dose of CPG 52364
NCT00547014 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants
NCT02670395 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers
NCT00797342 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 ·Status: COMPLETED ·Phase: PHASE1
-
Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
NCT00813670 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
NCT02539550 ·Status: COMPLETED ·Phase: PHASE1
-
PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions
NCT01362673 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers
NCT01580644 ·Status: COMPLETED ·Phase: PHASE1
-
Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection
NCT00542217 ·Status: COMPLETED ·Phase: PHASE1
-
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
NCT05434091 ·Status: WITHDRAWN ·Phase: PHASE1
-
Multiple Ascending Doses Study of CG400549
NCT01848470 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects
NCT01636141 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of EDG-15400 in Healthy Adults
NCT07177066 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers
NCT03096756 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
NCT01238679 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects
NCT01616277 ·Status: COMPLETED ·Phase: PHASE1